The Latin America, Middle East and Africa Large Molecule Drug Substance CDMO Market should witness market growth of 11.0% CAGR during the forecast period (2022-2028).
The development of CDMOs is being driven by their assistance in meeting deadlines and overcoming difficulties, like the fragility of the large molecule-based active compounds, in the early drug development stages. Numerous innovative techniques have been developed that combat the fragility and complexity issues of large molecules.
For example, techniques like encapsulation and buffer use work by promoting the stabilization of large molecules, thereby protecting them. The rising elderly population, worldwide growth of economy, and new product launches are propelling the growth of the pharmaceutical industry and CDMOs exponentially.
Similarly, the increasing preference for gene and cell therapies are advancing the growth of the biologics. This growth further perpetuates its positive effect on the originator biologics as well. One of the major drivers that are influencing the growth of biologics is the rising cancer therapies demand. As a result, there has been a steady increase in the number of large molecules being approved.
In this region, the healthcare industry has significantly grown and has become one of the GCC's most important sectors for promoting economic diversification. Consequently, public-private partnerships are being encouraged, and private businesses are compelled to build infrastructure for further developing the drug manufacturing processes. In addition, the increasing preference for preventive care over curative care by the younger, healthier population is pushing the sector positively.
The Brazil market dominated the LAMEA Large Molecule Drug Substance CDMO Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $295 million by 2028. The Argentina market is experiencing a CAGR of 11.6% during (2022-2028). Additionally, The UAE market would display a CAGR of 10.7% during (2022-2028).
Based on Application, the market is segmented into Mammalian, Microbial and Others. Based on Service, the market is segmented into Contract Manufacturing and Contract Development. Based on Contract Manufacturing Type, the market is segmented into Commercial and Clinical. Based on Contract Development Type, the market is segmented into Cell Line Development and Process Development. Based on End-user, the market is segmented into Biotech Companies, CRO and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eurofins Scientific SE, WuXi Biologics (Cayman), Inc, Catalent, Inc., Boehringer Ingelheim International GmbH, FUJIFILM Diosynth Biotechnologies Texas LLC (Fujifilm Corporation), Samsung Biologics Co., Ltd. (Samsung Group), Rentschler Biopharma SE, AGC Biologics, Inc. (AGC, Inc.), Recipharm AB (EQT AB), and Siegfried Holding AG.
The development of CDMOs is being driven by their assistance in meeting deadlines and overcoming difficulties, like the fragility of the large molecule-based active compounds, in the early drug development stages. Numerous innovative techniques have been developed that combat the fragility and complexity issues of large molecules.
For example, techniques like encapsulation and buffer use work by promoting the stabilization of large molecules, thereby protecting them. The rising elderly population, worldwide growth of economy, and new product launches are propelling the growth of the pharmaceutical industry and CDMOs exponentially.
Similarly, the increasing preference for gene and cell therapies are advancing the growth of the biologics. This growth further perpetuates its positive effect on the originator biologics as well. One of the major drivers that are influencing the growth of biologics is the rising cancer therapies demand. As a result, there has been a steady increase in the number of large molecules being approved.
In this region, the healthcare industry has significantly grown and has become one of the GCC's most important sectors for promoting economic diversification. Consequently, public-private partnerships are being encouraged, and private businesses are compelled to build infrastructure for further developing the drug manufacturing processes. In addition, the increasing preference for preventive care over curative care by the younger, healthier population is pushing the sector positively.
The Brazil market dominated the LAMEA Large Molecule Drug Substance CDMO Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $295 million by 2028. The Argentina market is experiencing a CAGR of 11.6% during (2022-2028). Additionally, The UAE market would display a CAGR of 10.7% during (2022-2028).
Based on Application, the market is segmented into Mammalian, Microbial and Others. Based on Service, the market is segmented into Contract Manufacturing and Contract Development. Based on Contract Manufacturing Type, the market is segmented into Commercial and Clinical. Based on Contract Development Type, the market is segmented into Cell Line Development and Process Development. Based on End-user, the market is segmented into Biotech Companies, CRO and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eurofins Scientific SE, WuXi Biologics (Cayman), Inc, Catalent, Inc., Boehringer Ingelheim International GmbH, FUJIFILM Diosynth Biotechnologies Texas LLC (Fujifilm Corporation), Samsung Biologics Co., Ltd. (Samsung Group), Rentschler Biopharma SE, AGC Biologics, Inc. (AGC, Inc.), Recipharm AB (EQT AB), and Siegfried Holding AG.
Scope of the Study
By Application
- Mammalian
- Microbial
- Others
By Service
- Contract Manufacturing
- Commercial
- Clinical
- Contract Development
- Cell Line Development
- Process Development
By End-user
- Biotech Companies
- CRO
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Eurofins Scientific SE
- WuXi Biologics (Cayman), Inc
- Catalent, Inc.
- Boehringer Ingelheim International GmbH
- FUJIFILM Diosynth Biotechnologies Texas LLC (Fujifilm Corporation)
- Samsung Biologics Co., Ltd. (Samsung Group)
- Rentschler Biopharma SE
- AGC Biologics, Inc. (AGC, Inc.)
- Recipharm AB (EQT AB)
- Siegfried Holding AG
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Large Molecule Drug Substance CDMO Market, by Application
1.4.2 LAMEA Large Molecule Drug Substance CDMO Market, by Service
1.4.3 LAMEA Large Molecule Drug Substance CDMO Market, by End-user
1.4.4 LAMEA Large Molecule Drug Substance CDMO Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Acquisition and Mergers
3.2.3 Geographical Expansions
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2019, Apr- 2022, Oct) Leading Players
3.3.3 Key Strategic Move: (Acquisitions and Mergers : 2018, Oct - 2022, Aug) Leading Players
Chapter 4. LAMEA Large Molecule Drug Substance CDMO Market by Application
4.1 LAMEA Mammalian Market by Country
4.2 LAMEA Microbial Market by Country
4.3 LAMEA Other Application Market by Country
Chapter 5. LAMEA Large Molecule Drug Substance CDMO Market by Service
5.1 LAMEA Contract Manufacturing Market by Country
5.2 LAMEA Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
5.2.1 LAMEA Commercial Market by Country
5.2.2 LAMEA Clinical Market by Country
5.3 LAMEA Contract Development Market by Country
5.4 LAMEA Large Molecule Drug Substance CDMO Market by Contract Development Type
5.4.1 LAMEA Cell Line Development Market by Country
5.4.2 LAMEA Process Development Market by Country
Chapter 6. LAMEA Large Molecule Drug Substance CDMO Market by End-user
6.1 LAMEA Biotech Companies Market by Country
6.2 LAMEA CRO Market by Country
6.3 LAMEA Others Market by Country
Chapter 7. LAMEA Large Molecule Drug Substance CDMO Market by Country
7.1 Brazil Large Molecule Drug Substance CDMO Market
7.1.1 Brazil Large Molecule Drug Substance CDMO Market by Application
7.1.2 Brazil Large Molecule Drug Substance CDMO Market by Service
7.1.2.1 Brazil Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
7.1.2.2 Brazil Large Molecule Drug Substance CDMO Market by Contract Development Type
7.1.3 Brazil Large Molecule Drug Substance CDMO Market by End-user
7.2 Argentina Large Molecule Drug Substance CDMO Market
7.2.1 Argentina Large Molecule Drug Substance CDMO Market by Application
7.2.2 Argentina Large Molecule Drug Substance CDMO Market by Service
7.2.2.1 Argentina Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
7.2.2.2 Argentina Large Molecule Drug Substance CDMO Market by Contract Development Type
7.2.3 Argentina Large Molecule Drug Substance CDMO Market by End-user
7.3 UAE Large Molecule Drug Substance CDMO Market
7.3.1 UAE Large Molecule Drug Substance CDMO Market by Application
7.3.2 UAE Large Molecule Drug Substance CDMO Market by Service
7.3.2.1 UAE Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
7.3.2.2 UAE Large Molecule Drug Substance CDMO Market by Contract Development Type
7.3.3 UAE Large Molecule Drug Substance CDMO Market by End-user
7.4 Saudi Arabia Large Molecule Drug Substance CDMO Market
7.4.1 Saudi Arabia Large Molecule Drug Substance CDMO Market by Application
7.4.2 Saudi Arabia Large Molecule Drug Substance CDMO Market by Service
7.4.2.1 Saudi Arabia Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
7.4.2.2 Saudi Arabia Large Molecule Drug Substance CDMO Market by Contract Development Type
7.4.3 Saudi Arabia Large Molecule Drug Substance CDMO Market by End-user
7.5 South Africa Large Molecule Drug Substance CDMO Market
7.5.1 South Africa Large Molecule Drug Substance CDMO Market by Application
7.5.2 South Africa Large Molecule Drug Substance CDMO Market by Service
7.5.2.1 South Africa Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
7.5.2.2 South Africa Large Molecule Drug Substance CDMO Market by Contract Development Type
7.5.3 South Africa Large Molecule Drug Substance CDMO Market by End-user
7.6 Nigeria Large Molecule Drug Substance CDMO Market
7.6.1 Nigeria Large Molecule Drug Substance CDMO Market by Application
7.6.2 Nigeria Large Molecule Drug Substance CDMO Market by Service
7.6.2.1 Nigeria Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
7.6.2.2 Nigeria Large Molecule Drug Substance CDMO Market by Contract Development Type
7.6.3 Nigeria Large Molecule Drug Substance CDMO Market by End-user
7.7 Rest of LAMEA Large Molecule Drug Substance CDMO Market
7.7.1 Rest of LAMEA Large Molecule Drug Substance CDMO Market by Application
7.7.2 Rest of LAMEA Large Molecule Drug Substance CDMO Market by Service
7.7.2.1 Rest of LAMEA Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
7.7.2.2 Rest of LAMEA Large Molecule Drug Substance CDMO Market by Contract Development Type
7.7.3 Rest of LAMEA Large Molecule Drug Substance CDMO Market by End-user
Chapter 8. Company Profiles
8.1 Teledyne FLIR LLC (Teledyne Technologies Incorporated)
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Recent strategies and developments:
8.1.4.1 Partnerships, Collaborations and Agreements:
8.1.4.2 Product Launches and Product Expansions:
8.1.5 SWOT Analysis
8.2 Hikvision Digital Technology Co., Ltd., (China Electronics Technology Group Corporation)
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Research & Development Expenses
8.2.4 Recent strategies and developments:
8.2.4.1 Partnerships, Collaborations, and Agreements:
8.2.4.2 Product Launches and Product Expansions:
8.3 Axis Communications AB (Canon, Inc.)
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.3.5.2 Product Launches and Product Expansions:
8.4 Bosch Security Systems GmbH (Robert Bosch GmbH)
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Product Launches and Product Expansions:
8.5 Avigilon Corporation (Motorola Solutions)
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional & Segmental Analysis
8.5.4 Research & Development Expenses
8.6 Hanwha Techwin Co., Ltd. (Hanwha Group)
8.6.1 Company Overview
8.6.2 Recent strategies and developments:
8.6.2.1 Partnerships, Collaborations, and Agreements:
8.6.2.2 Product Launches and Product Expansions:
8.7 Zhejiang Dahua Technology Co., Ltd.
8.7.1 Company Overview
8.7.2 Recent strategies and developments:
8.7.2.1 Product Launches and Product Expansions:
8.8 Zhejiang Uniview Technologies Co., Ltd. (Hangzhou Jiaozhi Technology Co., Ltd.)
8.8.1 Company Overview
8.8.2 Recent strategies and developments:
8.8.2.1 Partnerships, Collaborations, and Agreements:
Companies Mentioned
- Eurofins Scientific SE
- WuXi Biologics (Cayman), Inc
- Catalent, Inc.
- Boehringer Ingelheim International GmbH
- FUJIFILM Diosynth Biotechnologies Texas LLC (Fujifilm Corporation)
- Samsung Biologics Co., Ltd. (Samsung Group)
- Rentschler Biopharma SE
- AGC Biologics, Inc. (AGC, Inc.)
- Recipharm AB (EQT AB)
- Siegfried Holding AG
Methodology
LOADING...
